Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Electroshock therapy speeds improvement in schizophrenia patients

21.04.2005


Shock therapy, a controversial practice conjuring frightening images of behavior control, still has a place in schizophrenia treatment, a newly updated research review shows.



Although the data confirmed that antipsychotic drugs are still the first choice for schizophrenia treatment, they also showed that electroconvulsive, or shock, therapy clearly works, and combining both treatments can accelerate benefits to some patients, the review finds.

Dr. Prathap Tharyan, head of psychiatry at Christian Medical College in Tamil Nadu, India, and colleagues analyzed 26 randomized controlled trials, involving 1,485 adult patients, 798 of whom were treated with shock therapy. Trials were conducted in India, the United States, Thailand, Canada, Hungary and Nigeria.


The review appears in the most recent issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

“ The most significant finding is that ECT combined with antipsychotics is more effective than antipsychotics alone in producing rapid clinical improvement in people with schizophrenia,” Tharyan said. Rapid improvement of symptoms is potentially lifesaving, for instance, when a person with schizophrenia is suicidal.

The review also refutes a public perception that ECT is dangerous and causes brain damage and suggests that for some patients the side effects of shock therapy may be more tolerable than those of antipsychotic drugs.

ECT induces a seizure with electric stimulus shock, given by electrodes attached to the scalp. Seizures last from 25 to 30 seconds. Patients are given short-acting anesthetics and muscle relaxants to decrease anxiety and protect them from injury during muscle contractions. Patients generally receive ECT two to three times a week, usually for a total of eight to 12 treatments in a series.

The American Psychiatric Association supports use of ECT only to treat severe, disabling mental disorders. However, the National Institute for Clinical Excellence in the United Kingdom does not recommend general use of ECT for schizophrenia, although it may be indicated for catatonia.

About 2.2 million American adults, or 1.1 percent of the adult population, have schizophrenia, according to 2001 figures from the National Institute of Mental Health. Twenty percent of people with schizophrenia fail to respond to drug therapy alone.

Researchers used sophisticated statistical methods to reach conclusions based on data pooled from individual, randomized studies.

Studies used a variety of tests to measure psychiatric symptoms and psychological, social and occupational functioning.

Ten trials compared shock therapy directly with drug therapy. “When ECT given without antipsychotics is directly compared to treatment with antipsychotics alone … results strongly favor the medication group,” reviewers found. They also found “very limited data” suggesting that people treated with ECT are less likely to relapse.

Further, one trial indicated that the combination of ECT and antipsychotics offered significant advantages that were maintained beyond the short term.

Several trials assessed cognitive side effects, such as memory impairment. Others measured side effects often seen with antipsychotic drugs, such as tremor, slurred speech, inability to keep still, anxiety and paranoia. Some data indicated that these side effects were less severe with ECT than with antipsychotic drugs.

A small trial found more impairment with ECT and antipsychotics combined than antipsychotics alone. “However,” authors noted, “when re-tested nine weeks later, memory function had improved in both groups and no significant differences were detected.”

A very small trial showed a decline in visual memory after ECT compared with those who were given anesthesia and nothing else.

Dr. David Spiegel, professor of psychiatry at Stanford University School of Medicine, has used ECT to treat patients with depression but views its use in schizophrenia as a last resort.

“I would worry that in some of the studies, patients may not have been on an aggressive enough drug schedule to treat early symptoms rapidly,” Spiegel says. “You would have to include only studies where drug control was optimal.

“Lots of people — especially many with delusions — are still uncomfortable with ECT, although it’s terrific for depression,” Spiegel says.

ECT came into use in the late 1930s, but it waned in developed nations with the introduction of antipsychotics and antidepressants in the 1950s.

Tharyan says that in countries with few state-funded social services, ECT can be useful as the more rapid treatment because the impact of long-running schizophrenia can cause both patients and family caregivers to stop working. ECT is more available and less expensive than antipsychotics in many developing areas.

Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. The Cochrane Database of Systematic Reviews 2005, Issue 2

The Cochrane Collaboration is an international nonprofit, independent organization that produces and disseminates systematic reviews of health care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions.

Prathap Tharyan | EurekAlert!
Further information:
http://www.cochrane.org
http://www.hbns.org
http://www.cfah.org

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>